Regulus Therapeutics Inc. Stock News

Definitive Agreement for $34.6 Million in Gross Proceeds LA JOLLA, Calif. , Nov. 24, 2021 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today

Regulus Therapeutics Inc. (NASDAQ:RGLS)s traded shares stood at 1.5 million during the last session, with the companys beta value hitting 2.00. At the close of trading, the stocks price was $0.39, to imply a decrease of -5.85% or -$0.02 in intraday trading. The RGLS shares 52-week high remains $2.32, putting it -494.87% down since that Regulus Therapeutics Inc. (NASDAQ: RGLS) Just Learned Something New After This Weeks -7.94% Loss Read More »

Regulus Therapeutics (NASDAQ:RGLS) was downgraded by Zacks Investment Research from a hold rating to a sell rating in a research note issued to investors on Wednesday, Zacks.com reports. According to Zacks, Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Companys products aim to []

Zacks Investment Research lowered shares of Regulus Therapeutics (NASDAQ:RGLS) from a hold rating to a sell rating in a research note released on Wednesday morning, Zacks.com reports. According to Zacks, Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Companys products aim to treat []

Regulus Therapeutics Inc. (RGLS) CEO Jay Hagan on Q3 2021 Results - Earnings Call Transcript

Regulus (RGLS) delivered earnings and revenue surprises of -42.86% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

SAN DIEGO, Nov. 3, 2021 /PRNewswire/ --  Regulus Therapeutics Inc.  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (

Are these Webull penny stocks to buy or avoid right now? The post 5 Penny Stocks To Buy For Under $1 On Webull Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStock

Last week, the five biggest stock market losers declined between about 36% and 26%. Below is a look at each stock and what they may have in the cards going forward.

The stock price of Regulus Therapeutics Inc (NASDAQ: RGLS) fell over 20% pre-market today. This is why it happened.

SAN DIEGO, Sept. 30, 2021 /PRNewswire/ --  Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs

SAN DIEGO, Sept. 9, 2021 /PRNewswire/ --  Regulus Therapeutics Inc.  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs

Regulus Therapeutics' (RGLS) CEO Jay Hagan on Q2 2021 Results - Earnings Call Transcript

SAN DIEGO, Aug, 3, 2021 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (th

Looking for popular penny stocks to watch? Check these 3 out The post 3 Popular Penny Stocks For Your August 2021 Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennySt